Talha Khan
Pulmonary Disease · New Brunswick, NJNPI 1356573646
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,138 of the $2,482 with a category attached, or 86.1%. Intuitive Surgical accounts for 86.8% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $2,171, more than ten times the $46 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in NJ, where the typical reported total is $2,135.
Across 16 payments — averaging $155.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- AstraZeneca$125
- Ambu Inc.$57
- Philips North America LLC$46
- Vapotherm Inc$35
- Inspire Medical Systems, Inc.$25
- plus $40 from 2 others
What the payments were for
- Travel & lodging$2,13886%
- Food & beverage$34414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $2,155 |
| AstraZeneca | 1 | $125 |
| Ambu Inc. | 1 | $57 |
| Philips North America LLC | 1 | $46 |
| Vapotherm Inc | 1 | $35 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Abbott | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,088
- TEZSPIRE$125
How this compares
$2,482 in reported general payments places this provider in the 50th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 15 | $215,073 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,422 |
| Spiriva HandihalerTiotropium Bromide | 17 | $8,643 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $8,429 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $7,269 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 152 | $3,620 |
| Arnuity ElliptaFluticasone Furoate | 14 | $3,556 |
| Fluticasone Propionate | 98 | $1,802 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,091 |
| Montelukast Sodium | 73 | $658 |
| Prednisone | 19 | $103 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New Brunswick
- Reynold PanettieriNew Brunswick$1M
- Amar BukhariNew Brunswick$21K
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.